Intimation regarding closure of trading window
Awaiting price reaction for this filing.
Dr. Reddy's Laboratories has informed stock exchanges that a Board meeting is scheduled for Wednesday, July 23, 2025. The Board will consider and approve the Unaudited Standalone and Consolidated Financial Results for the quarter ending June 30, 2025 (Q1 FY26). Pursuant to SEBI Insider Trading Regulations, the trading window for dealing in the company's securities will be closed from June 24, 2025 to July 25, 2025 (both days inclusive). This means directors, promoters, employees, and other insiders are prohibited from trading in Dr. Reddy's shares during this period. The communication was signed by K Randhir Singh, Company Secretary and Compliance Officer.
Routine regulatory disclosure — no direct impact on stock price. However, the upcoming Q1 FY26 results announcement on July 23 could be a catalyst for stock movement. The trading window closure signals that insider activity will be restricted until results are publicly disclosed, which is standard practice and helps ensure fairness.